Altogether, these data support further development of HDAC inhibitors in combination with immunotherapy agents in the context of specific solid tumors, even in patients who have previously progressed on anti-PD-1 or PD-L1 ICIs, so as to prime anti-tumor immune response and counteract tumor immune resistance mechanisms. The gene discussed is HDAC9; the disease is neoplasm.